Hologen And Sysmex Establish Saibogen, A Joint Venture Using AI To Turn Routine Blood Test Data Into Clinical Intelligence

LONDON and KOBE, Japan, Nov 10 (Bernama) -- Hologen (HQ: London, UK; CEO: Roland Tegeder), a frontier AI company, and Sysmex Corporation (HQ: Kobe, Japan; President: Iwane Matsui), a global leader in hematology, today announced Saibogen, a blood intelligence company formed as a joint venture between the two companies. Saibogen will apply Hologen’s Large Medicine Models, generative AI models that learn the biology underpinning real-world healthcare data, to proprietary data generated by Sysmex hematology analyzers. The approach aims to unlock new insights from routine blood testing data, with no new instruments, reagents or samples, and to create new clinical value for healthcare professionals and researchers.

Hematology testing is one of the most widely performed laboratory investigations worldwide and often serves as a starting point for medical care. Sysmex hematology analyzers alone run approximately 3 billion¹ of these tests each year, producing a precise, standardized set of values that clinicians around the world rely on. With Saibogen, Sysmex and Hologen are launching a mission to uncover the hidden biological signals in data that Sysmex hematology analyzers already generate.